181 related articles for article (PubMed ID: 34586103)
1. Clinical development and current role of margetuximab for the treatment of breast cancer.
Tarantino P; Uliano J; Morganti S; Giugliano F; Crimini E; Curigliano G
Drugs Today (Barc); 2021 Sep; 57(9):551-558. PubMed ID: 34586103
[TBL] [Abstract][Full Text] [Related]
2. Margetuximab for the treatment of HER2-positive metastatic breast cancer.
Tarantino P; Morganti S; Uliano J; Giugliano F; Crimini E; Curigliano G
Expert Opin Biol Ther; 2021 Feb; 21(2):127-133. PubMed ID: 33238772
[TBL] [Abstract][Full Text] [Related]
3. Margetuximab in HER2-positive metastatic breast cancer.
Gradishar WJ; O'Regan R; Rimawi MF; Nordstrom JL; Rosales MK; Rugo HS
Future Oncol; 2023 May; 19(16):1099-1112. PubMed ID: 37170847
[TBL] [Abstract][Full Text] [Related]
4. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.
Bang YJ; Giaccone G; Im SA; Oh DY; Bauer TM; Nordstrom JL; Li H; Chichili GR; Moore PA; Hong S; Stewart SJ; Baughman JE; Lechleider RJ; Burris HA
Ann Oncol; 2017 Apr; 28(4):855-861. PubMed ID: 28119295
[TBL] [Abstract][Full Text] [Related]
5. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
[TBL] [Abstract][Full Text] [Related]
6. Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer.
Nur Husna SM; Wong KK
Mol Immunol; 2022 Dec; 152():45-54. PubMed ID: 36272249
[TBL] [Abstract][Full Text] [Related]
7. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
[TBL] [Abstract][Full Text] [Related]
8. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
9. Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy.
Li J; Lu Q; Zhou H; Xu F; Huang J; Hong R; Wang S
Anticancer Drugs; 2023 Aug; 34(7):892-895. PubMed ID: 36729856
[TBL] [Abstract][Full Text] [Related]
10. Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer.
Schlam I; Nunes R; Lynce F
Onco Targets Ther; 2022; 15():471-478. PubMed ID: 35509453
[TBL] [Abstract][Full Text] [Related]
11. Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era.
Mandó P; Rivero SG; Rizzo MM; Pinkasz M; Levy EM
Breast; 2021 Dec; 60():15-25. PubMed ID: 34454323
[TBL] [Abstract][Full Text] [Related]
12. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Rugo HS; Im SA; Cardoso F; Cortes J; Curigliano G; Musolino A; Pegram MD; Bachelot T; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Schwartz GN; Pluard TJ; Ricci F; Gwin WR; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Gal-Yam EN; Yerushalmi R; Fasching PA; Kaufman PA; Ashley EJ; Perez-Olle R; Hong S; Rosales MK; Gradishar WJ;
J Clin Oncol; 2023 Jan; 41(2):198-205. PubMed ID: 36332179
[No Abstract] [Full Text] [Related]
13. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
Kunte S; Abraham J; Montero AJ
Cancer; 2020 Oct; 126(19):4278-4288. PubMed ID: 32721042
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
15. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
16. Margetuximab: First Approval.
Markham A
Drugs; 2021 Apr; 81(5):599-604. PubMed ID: 33761116
[TBL] [Abstract][Full Text] [Related]
17. Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report.
Chang H; Hu T; Hu J; Ding T; Wang Q; Cheng J
Anticancer Drugs; 2023 Aug; 34(7):883-887. PubMed ID: 36730303
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.
Royce M; Osgood CL; Amatya AK; Fiero MH; Chang CJG; Ricks TK; Shetty KA; Kraft J; Qiu J; Song P; Charlab R; Yu J; King KE; Rastogi A; Janelsins B; Weinberg WC; Clouse K; Borders-Hemphill V; Brown L; Gomez-Broughton C; Li Z; Nguyen TT; Qiu Z; Ly AT; Chang S; Gao T; Tu CM; King-Kallimanis B; Pierce WF; Chiang K; Lee C; Goldberg KB; Leighton JK; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2022 Apr; 28(8):1487-1492. PubMed ID: 34916216
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
